BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.41% | 56.89% | 40.83% | 34.98% | 32.54% |
| Total Other Revenue | -- | -- | -- | -- | -29.55% |
| Total Revenue | 49.41% | 56.89% | 40.83% | 34.98% | 32.54% |
| Cost of Revenue | 17.45% | -12.40% | -17.20% | -7.72% | -24.67% |
| Gross Profit | 67.36% | 130.42% | 188.98% | 87.92% | 131.10% |
| SG&A Expenses | 42.67% | 38.62% | 25.68% | 28.50% | 20.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.81% | 15.91% | 3.74% | 10.88% | -2.54% |
| Operating Income | 239.98% | 246.51% | 88.06% | 164.52% | 142.32% |
| Income Before Tax | 151.88% | 102.16% | 58.85% | 62.46% | 83.24% |
| Income Tax Expenses | 714.53% | 98.90% | 156.18% | 77.58% | -76.76% |
| Earnings from Continuing Operations | 140.12% | 100.09% | 56.59% | 61.18% | 83.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 140.12% | 100.09% | 56.59% | 61.18% | 83.17% |
| EBIT | 239.98% | 246.51% | 88.06% | 164.52% | 142.32% |
| EBITDA | 231.63% | 252.01% | 93.26% | 169.59% | 144.74% |
| EPS Basic | 139.58% | 100.12% | 57.85% | 64.43% | 84.58% |
| Normalized Basic EPS | 183.91% | 102.17% | 56.67% | 65.59% | 74.83% |
| EPS Diluted | 132.57% | 100.06% | 58.02% | 64.43% | 84.65% |
| Normalized Diluted EPS | 179.95% | 102.07% | 56.67% | 65.59% | 74.83% |
| Average Basic Shares Outstanding | 1.50% | 1.37% | 2.97% | 9.10% | 9.15% |
| Average Diluted Shares Outstanding | 6.52% | 4.46% | 2.97% | 9.10% | 9.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |